Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Participants, who, in the opinion of the investigator, can and will comply with the requirements of the Protocol.~* Written informed consent obtained from the participant prior to performance of any study-specific procedure.~* Healthy participants as established by medical history and clinical examination before entering into the study.~* Man or woman aged 18-40 years, included, at the time of the first vaccination.~* Women of non-childbearing potential may be enrolled in the study.~* Women of childbearing potential may be enrolled in the study, if the participant:~  * Has practiced adequate contraception for one month prior to vaccination, and;~ * Has a negative pregnancy test result on the day of vaccination, and;~ * Has agreed to continue adequate contraception until the end of the study.~* Seronegative for HIV, as determined by laboratory screening tests. Participants documented to be positive to HIV will not be eligible for study participation.~* Seronegative for HSV-2 as determined by Western blot.~Exclusion Criteria:~Medical Conditions~* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccines.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Hypersensitivity to latex.~* Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, endocrine, or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Recurrent history or uncontrolled neurological disorders or seizures.~* Grade 2 or higher haematological and/or biochemical laboratory abnormality at screening.~* Body mass index ≤ 18 kg/m\^2 or ≥ 35 kg/m\^2.~* History of any form of ocular HSV infection, HSV-related erythema multiforme, or HSV-related neurological complications.~* Participants with symptoms suggestive of Coronavirus disease 2019 (COVID-19) infection within 14 days before the first study vaccination. Participants should be free of symptoms for at least 14 days.~* Participants with known COVID-19-positive contacts in the past 14 days before the first study vaccination.~Prior/Concomitant Therapy~* Use of any investigational or non-registered product other than the study vaccines during the period beginning 30 days before the first dose of study vaccine (Day -29 to Day 1), or planned use during the study period.~* Planned administration/administration of a vaccine not foreseen by the Protocol in the period starting 15 days before each dose and ending 15 days after each dose of study vaccine administration.~* Administration of long-acting immune-modifying drugs at any time during the study period.~* Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting three months before the first dose of study vaccine or planned administration during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting three months prior to the first study vaccine dose. For corticosteroids, this will mean prednisone equivalent ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.~* Prior receipt of another vaccine containing HSV-2 antigens. Prior/Concurrent Clinical Study Experience~* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.~Other Exclusions~* Pregnant or lactating woman.~* Woman planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- HSV lower dose formulation Group (Type: EXPERIMENTAL): Healthy participants, 18 to 40 years of age, receive two doses of the HSV lower dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
- Placebo Step 1 Group (Type: PLACEBO_COMPARATOR): Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
- HSV low dose formulation Group (Type: EXPERIMENTAL): Healthy participants, 18 to 40 years of age, receive two doses of the HSV low dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
- Placebo Step 2 Group (Type: PLACEBO_COMPARATOR): Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
- HSV medium dose formulation Group (Type: EXPERIMENTAL): Healthy participants, 18 to 40 years of age, receive two doses of the HSV medium dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
- Placebo Step 3 Group (Type: PLACEBO_COMPARATOR): Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
- HSV high dose formulation Group (Type: EXPERIMENTAL): Healthy participants, 18 to 40 years of age, receive two doses of the HSV high dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
- Placebo Step 4 Group (Type: PLACEBO_COMPARATOR): Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.

Based on this trial design, predict the completion outcome and termination type (if applicable).